Posology: The recommended oral dose of Feburic is 40 mg or 80 mg once daily without regard to food. The recommended starting dose of Feburic is 40 mg once daily. If serum uric acid is > 6.0 mg/dL (357 μmol/L) after 2-4 weeks, Feburic 80 mg once daily may be considered.
The 80 mg tablet can be divided into equal halves. In order to provide a 40 mg dose, the tablet should be split just before use. Prescribers should advise patients on how to break the tablets in half and to keep the other half for the next dose.
Feburic works sufficiently quickly to allow retesting of the serum uric acid after 2 weeks. The therapeutic target is to decrease and maintain serum uric acid below 6.0 mg/dL (357 μmol/L).
Gout flare prophylaxis of at least 6 months is recommended (see Precautions).
Elderly: No dose adjustment is required in the elderly (see Pharmacology: Pharmacokinetics under Actions).
Renal impairment: The efficacy and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance <30 mL/min, see Pharmacology: Pharmacokinetics under Actions).
No dose adjustment is necessary in patients with mild or moderate renal impairment.
Hepatic impairment: The efficacy and safety of febuxostat has not been studied in patients with severe hepatic impairment (Child Pugh Class C).
No dose adjustment is necessary in patients with mild hepatic impairment. Limited information is available in patients with moderate hepatic impairment.
Paediatric population: The safety and the efficacy of Feburic in children aged below the age of 18 years have not been established. No data are available.
Method of administration: Oral use.
Feburic should be taken by mouth and can be taken with or without food.